Ciprofloxacin therapy in cystic fibrosis

摘要: There is great need for an oral agent that could be used to treat pulmonary exacerbations in patients with cystic fibrosis. In this study, the use of ciprofloxacin as sole therapy was evaluated 18 39 infectious episodes; 13 episodes were classified severe, 19 moderate, and seven mild. Patients ranged age from eight 36 years (mean, 23 years). Dosage varied according severity disease, body size, susceptibility Pseudomonas isolate ciprofloxacin; dose 750 2,250 mg daily 1,800 mg). Ten received one course ciprofloxacin, repeated courses. The overall clinical response rate 82 percent. a initial treatment 96 percent patients. Those whom failed had been re-treated severely ill. Failure respond correlated poorly pretreatment minimal inhibitory concentration (MIC) values (0.6 microgram/ml failures versus 0.4 responses). not eradicated sputum any patients, although there marked reduction purulence bacterial counts. general, who did require re-treatment three months would again have susceptible organisms. When organisms became resistant (MIC greater than 2 micrograms/ml), they showed no concomitant new aminoglycoside or beta-lactam resistance. No serious toxicity occurred treatment. treated combination (tobramycin azlocillin), infecting reduced number, but eradication generally achieved. Increases MIC during therapy. Ciprofloxacin major advance bronchopulmonary infection